Skip to main content

Advertisement

SpringerLink
Log in

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

This work was designed to explore the ability of the self-administered Overactive Bladder 8-Question Awareness Tool (OAB-V8) to predict patient self-assessed effectiveness of antimuscarinic therapy on OAB symptoms in daily practice. Also, the ability of the tool to predict clinician evaluation of improvement was explored.

Methods

Patients of both genders, >18 years, with symptomatic OAB (score >8 on OAB-V8), and able to understand patient-reported outcome instruments were enrolled in this 3-month study. Patients were prescribed treatment with an antimuscarinic drug according to usual practice. Treatment effectiveness was assessed by the clinician and patient using the Clinical Global Impression of Improvement and Treatment Benefit Scale and by improved self-perceived quality of life using the Overactive Bladder Questionnaire Short Form (OAB-q SF) 3 months after initiating or changing an antimuscarinic therapy. Multivariate linear and logistic regression models were applied to explore the predictive validity of OAB-V8 scores at the baseline visit.

Results

A total of 246 patients (57.7 years, 67 % women) were analyzed. Based on baseline OAB-V8 scores, logistic regression models were capable of predicting clinical improvement and patient self-perceived treatment benefit in 70 % of cases. OAB-V8 scores significantly correlated with OAB-q SF domains at baseline: 0.790 and – 0.659 for symptom bother and health-related quality of life domains, respectively (p < 0.001 in both cases). Baseline OAB-V8 score was able to predict changes in both domains of the OAB-q SF: R 2 = 0.212 and 0.162 for symptom bother and health-related quality of life, respectively.

Conclusions

The OAB-V8 scale showed evidence of predictive validity for antimuscarinic effectiveness in daily practice based on physician assessment and patient self-assessment of improved quality of life and treatment benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

CGI-I:

Clinical Global Impression of Improvement

HRQL:

Health-related quality of life

OAB:

Overactive bladder

OAB-q SF:

Overactive Bladder Questionnaire Short Form

OAB-V8:

Overactive Bladder-Validated 8-question Awareness Tool

TBS:

Treatment Benefit Scale

References

  1. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  2. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29:4–20

    PubMed  Google Scholar 

  3. Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314

    Article  PubMed  Google Scholar 

  4. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336

    PubMed  CAS  Google Scholar 

  5. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

    Article  PubMed  CAS  Google Scholar 

  6. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG (2005) Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 22(4):381–394

    Article  PubMed  Google Scholar 

  7. Ricci JA, Baggish JS, Hunt TL et al (2001) Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 23:1245–1259

    Article  PubMed  CAS  Google Scholar 

  8. Berges R, Pientka L, Höfner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682–687

    Article  PubMed  CAS  Google Scholar 

  9. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C (2011) The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int 108(9):1459–1471

    Article  PubMed  Google Scholar 

  10. Dmochowski RR, Gomelsky A (2011) Update on the treatment of overactive bladder. Curr Opin Urol 21:286–290

    Article  PubMed  Google Scholar 

  11. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS (2006) Translating overactive bladder questionnaires in 14 languages. Urology 67:536–540

    Article  PubMed  Google Scholar 

  12. Arlandis A, Ruiz MR, Errando C et al (2012) Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish overactive bladder questionnaire-short form. Clin Drug Investig 32:523–532

    Article  PubMed  Google Scholar 

  13. Coyne KS, Lai JS, Zyczynski T, Kopp Z, Avery K, Abrams P (2004) An Overactive Bladder Symptom and Quality-of-Life Short Form: Development of the Overactive Bladder Questionnaire Short Form (OAB-q SF). 34th Joint Meeting of the International Continence Society and the International Urogynecological Association, 23–27 August 2004, Paris, France

  14. García-Portilla MP, Bascarán MT, Sáiz PA, Parellada M, Bousoño M, Bobes J (2011) Banco de instrumentos básicos para la práctica de la psiquiatría clínica. Comunicación y Ediciones Sanitarias, S.L. Majadahonda (Madrid), pp 231-238

  15. Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U (2008) Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 72:803–807

    Article  PubMed  CAS  Google Scholar 

  16. Errando-Smet C, Ruiz MA, Villacampa-Aubá F, Arlandis-Guzmán S, Rejas J, García-Vargas M (2012) Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder. Med Clin. doi:10.1016/j.medcli.2011.11.013

  17. Bech P (1993) Rating scales for psychopathology, health status, and quality of life. Springer, Berlin, pp 33–35

    Book  Google Scholar 

  18. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74

    Article  PubMed  CAS  Google Scholar 

  19. Val Jiménez A, Amorós Ballestero G, Martínez Visa P, Fernández Ferré ML, León Sanromà M (1992) Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test Morisky y Green. Aten Primaria 10:767–770

  20. Nunnally JC, Berstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York

    Google Scholar 

  21. Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574

    Article  PubMed  CAS  Google Scholar 

  22. Committee for Proprietary Medical Products (2002) Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence. European Agency for the Evaluation of Medicinal Products, London

    Google Scholar 

  23. Guy W (1976) Early clinical drug evaluation (ECDEU). Assessment manual. National Institute of Mental Health, Rockville

    Google Scholar 

  24. Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102–109

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank all participating patients, colleagues, and the staff of the institutions for their contributions to data collection. Special thanks to Mercedes García-Vargas for the idea of the study and her invaluable contribution in the initial steps of the study.

Conflicts of interest

This study was funded by Pfizer, S.L.U. Daniel Arumí, Isabel Lizarraga, and Javier Rejas are full-time employees of Pfizer. Miguel Ruiz received a grant from Pfizer, S.L.U. for data analysis. Editorial support was not hired. All other authors have no competing interests.

Author information

Authors and Affiliations

  1. Department of Urology, Hospital 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain

    Felipe Villacampa

  2. Department of Methodology, School of Psychology, Universidad Autónoma de Madrid, Madrid, Spain

    Miguel A. Ruiz

  3. Department of Urology, Fundación Puigvert, Barcelona, Spain

    Carlos Errando

  4. Department of Urology, Hospital Universitari I Politecnic La Fe, Valencia, Spain

    Salvador Arlandis

  5. Pfizer Inc., Madrid, Spain

    Daniel Arumí

  6. Medical Unit, Pfizer, S.L.U., Alcobendas, Madrid, Spain

    Isabel Lizarraga

  7. Health Economics and Outcomes Research Department, Pfizer, S.L.U., Alcobendas, Madrid, Spain

    Javier Rejas

Authors
  1. Felipe Villacampa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel A. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos Errando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvador Arlandis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Arumí
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isabel Lizarraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Javier Rejas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Villacampa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villacampa, F., Ruiz, M.A., Errando, C. et al. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool. Int Urogynecol J 24, 573–581 (2013). https://doi.org/10.1007/s00192-012-1921-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-012-1921-x

Keywords

Search

Navigation